1. Home
  2. BXSL vs RGEN Comparison

BXSL vs RGEN Comparison

Compare BXSL & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BXSL
  • RGEN
  • Stock Information
  • Founded
  • BXSL 2018
  • RGEN 1981
  • Country
  • BXSL United States
  • RGEN United States
  • Employees
  • BXSL N/A
  • RGEN N/A
  • Industry
  • BXSL Trusts Except Educational Religious and Charitable
  • RGEN Medical/Dental Instruments
  • Sector
  • BXSL Finance
  • RGEN Health Care
  • Exchange
  • BXSL Nasdaq
  • RGEN Nasdaq
  • Market Cap
  • BXSL 7.5B
  • RGEN 8.0B
  • IPO Year
  • BXSL N/A
  • RGEN N/A
  • Fundamental
  • Price
  • BXSL $31.65
  • RGEN $126.50
  • Analyst Decision
  • BXSL Buy
  • RGEN Buy
  • Analyst Count
  • BXSL 6
  • RGEN 12
  • Target Price
  • BXSL $31.38
  • RGEN $172.67
  • AVG Volume (30 Days)
  • BXSL 964.2K
  • RGEN 815.5K
  • Earning Date
  • BXSL 05-07-2025
  • RGEN 04-29-2025
  • Dividend Yield
  • BXSL 9.73%
  • RGEN N/A
  • EPS Growth
  • BXSL N/A
  • RGEN N/A
  • EPS
  • BXSL 3.14
  • RGEN N/A
  • Revenue
  • BXSL $1,380,706,000.00
  • RGEN $650,429,000.00
  • Revenue This Year
  • BXSL $12.37
  • RGEN $13.93
  • Revenue Next Year
  • BXSL $8.12
  • RGEN $14.35
  • P/E Ratio
  • BXSL $10.08
  • RGEN N/A
  • Revenue Growth
  • BXSL 16.76
  • RGEN 4.88
  • 52 Week Low
  • BXSL $25.89
  • RGEN $102.97
  • 52 Week High
  • BXSL $34.64
  • RGEN $182.52
  • Technical
  • Relative Strength Index (RSI)
  • BXSL 64.90
  • RGEN 44.61
  • Support Level
  • BXSL $29.07
  • RGEN $123.10
  • Resistance Level
  • BXSL $30.04
  • RGEN $135.47
  • Average True Range (ATR)
  • BXSL 0.52
  • RGEN 6.98
  • MACD
  • BXSL 0.34
  • RGEN -0.97
  • Stochastic Oscillator
  • BXSL 98.20
  • RGEN 25.20

About BXSL Blackstone Secured Lending Fund of Beneficial Interest

Blackstone Secured Lending Fund is a non-diversified, closed-end management investment company. The investment objectives of the company are to generate current income and, to a lesser extent, long-term capital appreciation. The company seeks to achieve its investment objectives by investing in originated loans and other securities, including syndicated loans of private U.S. companies, typically in the form of first lien senior secured and unitranche loans, unsecured and subordinated loans, and other securities.

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

Share on Social Networks: